Interferon gamma inhalation - RELIEF THERAPEUTICS Holding

Drug Profile

Interferon gamma inhalation - RELIEF THERAPEUTICS Holding

Latest Information Update: 22 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator mondoBIOTECH
  • Developer RELIEF THERAPEUTICS Holding
  • Class Antineoplastics; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity No
  • Available For Licensing Yes - Idiopathic pulmonary fibrosis

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 19 Sep 2016 Interferon gamma inhalation is available for licensing in USA, Europe as of 19 Sep 2016.
  • 19 Sep 2016 Phase-II clinical trials in Idiopathic pulmonary fibrosis (Inhalation)
  • 19 Sep 2016 Interferon gamma inhalation - RELIEF THERAPEUTICS receives Orphan Drug status for Idiopathic pulmonary fibrosis in European Union before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top